Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kristin Narayan"'
Autor:
Pete Schmidt, Jean Gong, Kristin Narayan, Deepali Gupta, Frank Engler, Yong Li, Amanda Copans, Ed Campanaro
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 5, Pp 1365-1377 (2023)
Abstract Introduction Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we repor
Externí odkaz:
https://doaj.org/article/3261c8f84c034becba407ea96fc397b5
Autor:
Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A. Hay, Patrick Smith, Frank Engler, Rienk Jeeninga, Saskia Smits, Jose Trevejo, Zach Shriver, David Oldach
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 574-582 (2019)
Background: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non
Externí odkaz:
https://doaj.org/article/05bb3efbad9847a08d9ae6f127d94fdb
Autor:
Ema T Crooks, Tommy Tong, Bimal Chakrabarti, Kristin Narayan, Ivelin S Georgiev, Sergey Menis, Xiaoxing Huang, Daniel Kulp, Keiko Osawa, Janelle Muranaka, Guillaume Stewart-Jones, Joanne Destefano, Sijy O'Dell, Celia LaBranche, James E Robinson, David C Montefiori, Krisha McKee, Sean X Du, Nicole Doria-Rose, Peter D Kwong, John R Mascola, Ping Zhu, William R Schief, Richard T Wyatt, Robert G Whalen, James M Binley
Publikováno v:
PLoS Pathogens, Vol 11, Iss 5, p e1004932 (2015)
Eliciting broad tier 2 neutralizing antibodies (nAbs) is a major goal of HIV-1 vaccine research. Here we investigated the ability of native, membrane-expressed JR-FL Env trimers to elicit nAbs. Unusually potent nAb titers developed in 2 of 8 rabbits
Externí odkaz:
https://doaj.org/article/65b7f896418649c1899f642d72673ccb
Autor:
Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Paul Ambrose, Laura M. Walker
Publikováno v:
Science Translational Medicine. 15
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 (COVID-19). However, the induction of multiple layers of immunity after
Autor:
Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne, Russel R. Bakken, Jeffrey W. Koehler, Korey L. Delp, Christopher P. Stefan, Raina Kumar, Jeffrey R. Kugelman, Alicia M. Moreau, Xiankun Zeng, John M. Dye, Andrew S. Herbert, Kristin Narayan, Laura M. Walker
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syr
Autor:
Evan Tarbell, Scott A Van Wart, Myra Popejoy, Kristin Narayan, Ellie Hershberger, Xia Pu, Jean Gong, Christopher M Rubino, Andrew Santulli, Paul Ambrose
Publikováno v:
Open Forum Infectious Diseases. 9
Background ADI is a fully human IgG1 monoclonal antibody engineered to have an extended half-life with high potency and broad neutralization against SARS-CoV-2 and other SARS-like coronaviruses. The goal of our analysis was to develop a QSP model in
Autor:
Xia Pu, Jean Gong, Ed Campanaro, Kristin Narayan, Deepali Gupta, Frank Engler, Amanda Copans, Pete Schmidt
Publikováno v:
Open Forum Infectious Diseases. 9
Background Adintrevimab is a fully human IgG1 monoclonal antibody engineered to have potent and broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like CoVs with pandemic potential. Adintrevimab i
Autor:
Kathryn Mahoney, Kristin Narayan, Natalia Betancourt, Yong Li, Deepali Gupta, Pamela Hawn, Pete Schmidt, Myra Popejoy
Publikováno v:
Open Forum Infectious Diseases. 9
Background Peak SARS-CoV-2 viral replication occurs in the upper respiratory tract in presymptomatic and early symptomatic phases. Administration of a monoclonal antibody may be most beneficial in the early time period immediately after symptom onset
Autor:
Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Laura M. Walker
Publikováno v:
medRxiv
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against COVID-19. However, the induction of multiple layers of immunity following SARS-CoV-2 exposure ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b11b2c4bdea6c95499b1a7f867d120
https://europepmc.org/articles/PMC9603828/
https://europepmc.org/articles/PMC9603828/
Autor:
Patrick F. Smith, Susan Sloan, Ellie Hershberger, David Oldach, Saskia Smits, Zach Shriver, Catherine A. Hay, Rienk E. Jeeninga, Frank Engler, Jose M. Trevejo, Kristin Narayan
Publikováno v:
EBioMedicine, Vol 40, Iss, Pp 574-582 (2019)
EBioMedicine
EBioMedicine
Background: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non